[{"id":"18460073-b219-4680-b839-36cecdb58964","acronym":"CALGB-40601","url":"https://clinicaltrials.gov/study/NCT00770809","created_at":"2021-01-17T17:29:01.763Z","updated_at":"2025-02-25T16:36:00.390Z","phase":"Phase 3","brief_title":"Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery","source_id_and_acronym":"NCT00770809 - CALGB-40601","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • lapatinib • Herzuma (trastuzumab-pkrb) • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 305","initiation":"Initiation: 12/01/2008","start_date":" 12/01/2008","primary_txt":" Primary completion: 01/31/2014","primary_completion_date":" 01/31/2014","study_txt":" Completion: 07/10/2025","study_completion_date":" 07/10/2025","last_update_posted":"2025-02-06"},{"id":"0a161a88-300c-46f6-886d-a1fdcd0ce1df","acronym":"","url":"https://clinicaltrials.gov/study/NCT02158507","created_at":"2021-01-18T10:02:31.452Z","updated_at":"2025-02-25T13:11:14.212Z","phase":"","brief_title":"Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer","source_id_and_acronym":"NCT02158507","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" HER-2 • PGR • BRCA1 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA mutation","tags":["HER-2 • PGR • BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 09/04/2014","start_date":" 09/04/2014","primary_txt":" Primary completion: 07/22/2021","primary_completion_date":" 07/22/2021","study_txt":" Completion: 07/22/2021","study_completion_date":" 07/22/2021","last_update_posted":"2025-02-03"},{"id":"c8ac7e17-715c-41d2-9bce-18f5ac018a38","acronym":"DESTINY-Breast02","url":"https://clinicaltrials.gov/study/NCT03523585","created_at":"2021-01-18T17:20:52.524Z","updated_at":"2025-02-25T15:07:36.634Z","phase":"Phase 3","brief_title":"DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]","source_id_and_acronym":"NCT03523585 - DESTINY-Breast02","lead_sponsor":"Daiichi Sankyo","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 608","initiation":"Initiation: 08/01/2018","start_date":" 08/01/2018","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-11-05"},{"id":"bbcbd72b-f6e0-4631-9945-f8a4ce0a71ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT01273610","created_at":"2021-01-18T05:09:07.934Z","updated_at":"2025-02-25T13:16:34.395Z","phase":"Phase 2","brief_title":"Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT01273610","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/20/2011","start_date":" 04/20/2011","primary_txt":" Primary completion: 02/22/2018","primary_completion_date":" 02/22/2018","study_txt":" Completion: 02/22/2025","study_completion_date":" 02/22/2025","last_update_posted":"2024-06-18"},{"id":"07559a56-04b6-451e-84a1-341907a657e2","acronym":"LOGiC","url":"https://clinicaltrials.gov/study/NCT00680901","created_at":"2021-01-18T02:32:43.490Z","updated_at":"2024-07-02T16:34:26.181Z","phase":"Phase 3","brief_title":"LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib","source_id_and_acronym":"NCT00680901 - LOGiC","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • capecitabine • oxaliplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 545","initiation":"Initiation: 06/04/2008","start_date":" 06/04/2008","primary_txt":" Primary completion: 09/24/2012","primary_completion_date":" 09/24/2012","study_txt":" Completion: 01/22/2025","study_completion_date":" 01/22/2025","last_update_posted":"2024-06-13"},{"id":"b4084e04-80e0-4936-af0c-62552e92f11e","acronym":"DETECT III","url":"https://clinicaltrials.gov/study/NCT01619111","created_at":"2021-01-18T06:56:21.591Z","updated_at":"2024-07-02T16:34:58.993Z","phase":"Phase 3","brief_title":"DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs","source_id_and_acronym":"NCT01619111 - DETECT III","lead_sponsor":"Prof. Wolfgang Janni","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • lapatinib • capecitabine • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 105","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 01/01/2022","study_completion_date":" 01/01/2022","last_update_posted":"2024-06-04"},{"id":"87923196-97d9-4e54-a07f-3d2558fab429","acronym":"","url":"https://clinicaltrials.gov/study/NCT02101905","created_at":"2021-01-18T09:41:49.492Z","updated_at":"2024-07-02T16:35:07.246Z","phase":"Phase 1","brief_title":"Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma","source_id_and_acronym":"NCT02101905","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR amplification","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 03/13/2014","start_date":" 03/13/2014","primary_txt":" Primary completion: 10/19/2021","primary_completion_date":" 10/19/2021","study_txt":" Completion: 10/19/2024","study_completion_date":" 10/19/2024","last_update_posted":"2024-04-29"},{"id":"90e2c2df-d5c6-4f93-8b0d-0ff266e30b82","acronym":"","url":"https://clinicaltrials.gov/study/NCT01306045","created_at":"2021-01-18T05:18:49.422Z","updated_at":"2024-07-02T16:35:10.788Z","phase":"Phase 2","brief_title":"Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies","source_id_and_acronym":"NCT01306045","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • sunitinib • lapatinib • Koselugo (selumetinib) • MK-2206"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 647","initiation":"Initiation: 02/08/2011","start_date":" 02/08/2011","primary_txt":" Primary completion: 02/12/2014","primary_completion_date":" 02/12/2014","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-09"},{"id":"068bd033-5d5c-40ce-a385-1c9ba82a08d5","acronym":"LAPATAM","url":"https://clinicaltrials.gov/study/NCT00424164","created_at":"2021-01-18T01:29:37.157Z","updated_at":"2024-07-02T16:35:15.573Z","phase":"Phase 1","brief_title":"Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT00424164 - LAPATAM","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • tamoxifen • Soltamox (tamoxifen citrate)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 11/01/2006","start_date":" 11/01/2006","primary_txt":" Primary completion: 06/01/2009","primary_completion_date":" 06/01/2009","study_txt":" Completion: 05/28/2010","study_completion_date":" 05/28/2010","last_update_posted":"2024-03-08"},{"id":"68ee6666-a2a3-4022-9809-88a75276636f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04608409","created_at":"2024-03-01T20:31:47.689Z","updated_at":"2024-07-02T16:35:16.832Z","phase":"Phase 1","brief_title":"Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer","source_id_and_acronym":"NCT04608409","lead_sponsor":"Frederick R. Ueland, M.D.","biomarkers":" ABCB1","pipe":" | ","alterations":" ABCB1 expression","tags":["ABCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABCB1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • lapatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-01"},{"id":"f06e2b3b-190c-464f-ad53-5bf7da6d993f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03500380","created_at":"2021-01-18T17:14:21.163Z","updated_at":"2024-07-02T16:35:18.748Z","phase":"Phase 2/3","brief_title":"A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases","source_id_and_acronym":"NCT03500380","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • capecitabine • Aidixi (disitamab vedotin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 301","initiation":"Initiation: 04/24/2018","start_date":" 04/24/2018","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-20"},{"id":"7d4f5eec-d35e-4cf9-94e4-4da7039b90db","acronym":"","url":"https://clinicaltrials.gov/study/NCT01300962","created_at":"2021-01-18T05:17:21.485Z","updated_at":"2025-02-25T15:51:43.149Z","phase":"Phase 1","brief_title":"Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT01300962","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib • capecitabine • Piqray (alpelisib) • buparlisib (AN2025)"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 08/01/2011","start_date":" 08/01/2011","primary_txt":" Primary completion: 02/07/2017","primary_completion_date":" 02/07/2017","study_txt":" Completion: 12/31/2018","study_completion_date":" 12/31/2018","last_update_posted":"2023-12-04"},{"id":"9691f487-0085-4e15-862b-15967cf70ec4","acronym":"TULIP","url":"https://clinicaltrials.gov/study/NCT03262935","created_at":"2021-01-18T16:07:05.359Z","updated_at":"2024-07-02T16:35:32.477Z","phase":"Phase 3","brief_title":"SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT03262935 - TULIP","lead_sponsor":"Byondis B.V.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Jivadco (trastuzumab duocarmazine)"],"overall_status":"Completed","enrollment":" Enrollment 437","initiation":"Initiation: 12/15/2017","start_date":" 12/15/2017","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2023-10-19"},{"id":"04811cee-2d36-4b3c-a734-0af0735d2ac3","acronym":"RTOG 1119","url":"https://clinicaltrials.gov/study/NCT01622868","created_at":"2021-01-18T06:57:43.966Z","updated_at":"2024-07-02T16:35:33.018Z","phase":"Phase 2","brief_title":"Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer","source_id_and_acronym":"NCT01622868 - RTOG 1119","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 12/06/2012","start_date":" 12/06/2012","primary_txt":" Primary completion: 12/30/2019","primary_completion_date":" 12/30/2019","study_txt":" Completion: 05/20/2022","study_completion_date":" 05/20/2022","last_update_posted":"2023-10-17"},{"id":"a140800b-3cce-4ffb-b56e-111439542768","acronym":"TRYHARD","url":"https://clinicaltrials.gov/study/NCT01711658","created_at":"2021-01-18T07:27:31.429Z","updated_at":"2025-02-25T13:18:00.322Z","phase":"Phase 2","brief_title":"TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.","source_id_and_acronym":"NCT01711658 - TRYHARD","lead_sponsor":"Radiation Therapy Oncology Group","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" CDKN2A negative","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • lapatinib"],"overall_status":"Completed","enrollment":" Enrollment 142","initiation":"Initiation: 03/15/2013","start_date":" 03/15/2013","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 09/21/2022","study_completion_date":" 09/21/2022","last_update_posted":"2023-10-17"},{"id":"14f82f5c-e429-4d17-9a3b-88bdc7d125c9","acronym":"ROME","url":"https://clinicaltrials.gov/study/NCT04591431","created_at":"2021-01-19T20:28:32.767Z","updated_at":"2025-02-25T13:53:27.554Z","phase":"Phase 2","brief_title":"The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy","source_id_and_acronym":"NCT04591431 - ROME","lead_sponsor":"Fondazione per la Medicina Personalizzata","biomarkers":" PD-L1 • BRAF","pipe":"","alterations":" ","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tecentriq (atezolizumab) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • everolimus • lapatinib • Alecensa (alectinib) • Perjeta (pertuzumab) • Iclusig (ponatinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Talzenna (talazoparib) • Piqray (alpelisib) • Retevmo (selpercatinib) • Alunbrig (brigatinib) • Gavreto (pralsetinib) • Pemazyre (pemigatinib) • ipatasertib (RG7440) • Tepmetko (tepotinib) • itacitinib (INCB039110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-03"},{"id":"4c36c373-716f-497a-a29b-0072de81b6ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT00455039","created_at":"2021-01-18T01:36:46.990Z","updated_at":"2024-07-02T16:35:40.236Z","phase":"Phase 2","brief_title":"INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients","source_id_and_acronym":"NCT00455039","lead_sponsor":"University of New Mexico","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/31/2023","start_date":" 07/31/2023","primary_txt":" Primary completion: 07/31/2023","primary_completion_date":" 07/31/2023","study_txt":" Completion: 07/31/2023","study_completion_date":" 07/31/2023","last_update_posted":"2023-08-11"},{"id":"01c28c82-a9b1-4732-b168-15b5fcf2427e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01138384","created_at":"2021-01-18T04:31:34.030Z","updated_at":"2025-02-25T13:15:56.714Z","phase":"Phase 1/2","brief_title":"Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT01138384","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • foretinib (GSK1363089)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 10/27/2010","start_date":" 10/27/2010","primary_txt":" Primary completion: 05/14/2014","primary_completion_date":" 05/14/2014","study_txt":" Completion: 02/13/2015","study_completion_date":" 02/13/2015","last_update_posted":"2023-08-04"},{"id":"49b9686c-a937-47ff-9c96-99a7a0b8f8ba","acronym":"HELEX","url":"https://clinicaltrials.gov/study/NCT00999804","created_at":"2021-01-18T03:54:31.931Z","updated_at":"2025-02-25T13:15:16.095Z","phase":"Phase 2","brief_title":"Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy","source_id_and_acronym":"NCT00999804 - HELEX","lead_sponsor":"Baylor Breast Care Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • lapatinib • letrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 11/01/2014","primary_completion_date":" 11/01/2014","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2023-06-16"},{"id":"353fd20f-f910-4d8d-b16c-ceb523b8a52b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03084939","created_at":"2021-01-18T15:11:50.535Z","updated_at":"2024-07-02T16:35:48.796Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT03084939","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • Kadcyla (ado-trastuzumab emtansine) • capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 351","initiation":"Initiation: 04/24/2017","start_date":" 04/24/2017","primary_txt":" Primary completion: 11/23/2018","primary_completion_date":" 11/23/2018","study_txt":" Completion: 03/14/2023","study_completion_date":" 03/14/2023","last_update_posted":"2023-05-08"},{"id":"1e301931-7462-4345-89d2-a94fd023f785","acronym":"CTRIAL-IE (ICORG) 11-10","url":"https://clinicaltrials.gov/study/NCT01526369","created_at":"2021-01-18T06:26:05.581Z","updated_at":"2024-07-02T16:35:51.292Z","phase":"Phase 3","brief_title":"A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer","source_id_and_acronym":"NCT01526369 - CTRIAL-IE (ICORG) 11-10","lead_sponsor":"Cancer Trials Ireland","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • lapatinib"],"overall_status":"Completed","enrollment":" Enrollment 75","initiation":"Initiation: 02/13/2012","start_date":" 02/13/2012","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 02/17/2023","study_completion_date":" 02/17/2023","last_update_posted":"2023-04-06"},{"id":"8d64e7ea-9824-4b7f-adc3-5e411973849a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00841828","created_at":"2021-01-18T03:12:16.157Z","updated_at":"2025-02-25T13:14:40.506Z","phase":"Phase 2","brief_title":"Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients","source_id_and_acronym":"NCT00841828","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • lapatinib • cyclophosphamide • epirubicin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 102","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 12/01/2011","primary_completion_date":" 12/01/2011","study_txt":" Completion: 12/01/2013","study_completion_date":" 12/01/2013","last_update_posted":"2023-03-31"},{"id":"ea90660c-49af-4b83-829a-76d449a7f624","acronym":"","url":"https://clinicaltrials.gov/study/NCT00281658","created_at":"2021-01-18T00:57:33.665Z","updated_at":"2024-07-02T16:35:55.790Z","phase":"Phase 3","brief_title":"Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2","source_id_and_acronym":"NCT00281658","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" HER-2 • PIK3CA • PTEN • KIT","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • PIK3CA mutation • PTEN mutation • PTEN-L","tags":["HER-2 • PIK3CA • PTEN • KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • PIK3CA mutation • PTEN mutation • PTEN-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • lapatinib"],"overall_status":"Completed","enrollment":" Enrollment 444","initiation":"Initiation: 01/02/2006","start_date":" 01/02/2006","primary_txt":" Primary completion: 06/18/2010","primary_completion_date":" 06/18/2010","study_txt":" Completion: 11/23/2021","study_completion_date":" 11/23/2021","last_update_posted":"2023-02-10"},{"id":"4b8ceee7-908a-4445-958c-c977257ae44f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00807859","created_at":"2021-01-18T03:04:10.693Z","updated_at":"2024-07-02T16:36:00.698Z","phase":"Phase 1","brief_title":"Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer","source_id_and_acronym":"NCT00807859","lead_sponsor":"Amgen","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • lapatinib • capecitabine • trebananib (AMG 386)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 03/09/2009","start_date":" 03/09/2009","primary_txt":" Primary completion: 02/27/2014","primary_completion_date":" 02/27/2014","study_txt":" Completion: 10/19/2015","study_completion_date":" 10/19/2015","last_update_posted":"2022-11-08"}]